Impact of Switching to Continuous Release Dopamine Agonists
Public ClinicalTrials.gov record NCT00465452. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
The Impact of Switching to Continuous Release Dopamine Agonists on Non-Motor Side Effects
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The purpose of this proposal is to determine if switching PD patients treated with pramipexole to ropinirole CR reduces the non-motor side effects frequently experienced by these patients. Side effects that we will monitor in particular include somnolence, peripheral edema, cognitive decline with and without hallucinations. PD patients followed in the MUO Neurology Clinic who are being treated with pramipexole and have evidence of at least one of the following symptoms: somnolence, cognitive impairment with or without hallucinations, or peripheral edema will be offered the opportunity to participate in this study.
Study identification
- NCT ID
- NCT00465452
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 11 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 55 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Dec 31, 2006
- Primary completion
- Feb 28, 2009
- Completion
- Nov 30, 2011
- Last update posted
- May 15, 2025
2007 – 2011
United States locations
- U.S. sites
- 1
- U.S. states
- 1
- U.S. cities
- 1
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Medical University of Ohio | Toledo | Ohio | 43614 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Recently updated Parkinson Disease trials
Other public records listing Parkinson Disease. Sorted by last update posted; newest first. Not a recommendation.
- NCT07752355: Young Onset Parkinson's Disease Subtypes and Pathogenic Mechanisms Recruiting
- NCT07748962: Decoding the Neural Mechanisms Underlying Postural Instability and Gait Dysfunction in Parkinson's Disease Not yet recruiting
- NCT07432958: A Study to Evaluate the Effectiveness of Two Doses of AP-472 as Adjunctive Therapy to Levodopa in Parkinson's Disease (PD) Participants With Motor Fluctuations Recruiting
- NCT07701785: Superior Parietal iTBS for PD-MCI Recruiting
- NCT04804202: Virtual Cycling Environments for Persons With Parkinson Disease Recruiting
- NCT06087926: Apathy in Parkinson Disease TMS Study Recruiting
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00465452, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted May 15, 2025 · Synced Sep 9, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT00465452 live on ClinicalTrials.gov.